Search Results | Blood | American Society of Hematology

1-20 of 198

2 3 4 5

Sort by

Sort Order Select

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven Howard Swerdlow, Kenneth C Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew Feldman, Falko Fend, Jonathan W Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L King, Gilles Andre Salles, Jesus F. San-Miguel, John F. Seymour, Steven P Treon, Julie Vose, Emanuele Zucca, Ranjana Advani, Stephen M. Ansell, Wing-Yan Au, Carlos Barrionuevo, P Leif Bergsagel, Wing C. Chan, Jeffrey I Cohen, Andrew John Davies, Brunangelo Falini, Irene M Ghobrial, John R Goodlad, John G Gribben, Eric D. Hsi, Brad S. Kahl, Won Seog Kim, Shaji K Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P Link, Armando López-Guillermo, María-Victoria Mateos, Elizabeth A. Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Dr, Astrid Pavlovsky, Stefano A Pileri, Professor, Miguel A Piris, Barbara Pro, S. Vincent Vincent Rajkumar, Steven T Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M Smith, Louis M Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N Winter, Andrew D. Zelenetz

Blood blood.2022015851.

DOI: https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

POD24 in follicular lymphoma: time to be “wise”

John P. Leonard

Blood (2022) 139 (11): 1609–1610.

DOI: https://doi.org/10.1182/blood.2021013437

Published: 2022

Journal Articles

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard

Blood (2022) 139 (8): 1147–1159.

DOI: https://doi.org/10.1182/blood.2021011679

Published: 2022

Includes: Supplemental data

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

DOI: https://doi.org/10.1182/blood-2021-145495

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

DOI: https://doi.org/10.1182/blood-2021-148199

Published: 2021

Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2021) 138 (Supplement 1): 523.

DOI: https://doi.org/10.1182/blood-2021-151266

Published: 2021

Journal Articles

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Paul M. Barr, Hongli Li, Brian K. Link, Christopher R. Flowers, Richard Burack, Heiko Schöder, Michael L. Leblanc, Oliver Weigert, Alex F. Herrera, David M. Weinstock, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2021) 138 (Supplement 1): 2425.

DOI: https://doi.org/10.1182/blood-2021-146182

Published: 2021

Journal Articles

Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool

Rachael M. Andrie, John M. Burke, Ian W. Flinn, John P. Leonard, Jeff P. Sharman, Timothy A. Quill, Kristen Rosenthal, Christopher R. Flowers

Blood (2021) 138 (Supplement 1): 1922.

DOI: https://doi.org/10.1182/blood-2021-152937

Published: 2021

Journal Articles

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Deborah M. Stephens, Hongli Li, Louis S. Constine, John P. Leonard, Brad S. Kahl, Joo Y Song, Michael L. Leblanc, Thomas J. Fitzgerald, Sonali M. Smith, Jonathan W. Friedberg, Dan O. Persky

Blood (2021) 138 (Supplement 1): 1423.

DOI: https://doi.org/10.1182/blood-2021-147938

Published: 2021

Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell

Blood (2021) 137 (5): 637–645.

DOI: https://doi.org/10.1182/blood.2019004753

Published: 2021

Includes: Supplemental data

Journal Articles

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Kristen Rosenthal, PhD, Jeremy S Abramson, MD MMSc, Farrukh T Awan, MD, John P. Leonard, MD, Julie M. Vose, MD MBA, Timothy A Quill, PhD, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-139818

Published: 2020

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-136023

Published: 2020

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Samuel Yamshon, MD, Peter Martin, FRCPC, MD MS, Bijal Shah, MD, Stephen J. Schuster, MD, Paul J Christos, Dr.P.H., M.S., Amelyn Rodriguez, BSN, RN, OCN, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Sarah C. Rutherford, MD, John N. Allan, MD, John P. Leonard, MD, Jia Ruan, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

DOI: https://doi.org/10.1182/blood-2020-138731

Published: 2020

Journal Articles

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Amy S. Ruppert, PhD, Levi D. Pederson, MS, Michael V. Knopp, MD PhD, David Poon, BS, Jun Zhang, PhD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD MSSc, Lawrence H. Schwartz, MD, Wyndham H. Wilson, MD PhD, John P. Leonard, MD, Nancy L. Bartlett, MD, Heiko Schöder, MD

Blood (2020) 136 (Supplement 1): 50.

DOI: https://doi.org/10.1182/blood-2020-139979

Published: 2020

Journal Articles

Evaluation of the Prognostic Utility of Bone Marrow Biopsy in Diffuse Large B-Cell Lymphoma: A SEER-Medicare Linked Database Analysis

Danny Luan, MPH, Yiyuan Wu, MS, Jordan S. Goldstein, MDMSc, Sarah C. Rutherford, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-134950

Published: 2020

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

DOI: https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells

Rossella Marullo, MDPhD, Maria Victoria Revuelta, PhD, Nahuel Zamponi, PhD, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, Giorgio Inghirami, MD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2020) 136 (Supplement 1): 18.

DOI: https://doi.org/10.1182/blood-2020-141464

Published: 2020

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-136422

Published: 2020

Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett

Blood (2020) 135 (25): 2224–2234.

DOI: https://doi.org/10.1182/blood.2019003277

Published: 2020

Includes: Supplemental data

2 3 4 5

NARROW

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee

POD24 in follicular lymphoma: time to be “wise”

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Evaluation of the Prognostic Utility of Bone Marrow Biopsy in Diffuse Large B-Cell Lymphoma: A SEER-Medicare Linked Database Analysis

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only